Related Experiment Videos
Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma
G Asaithambi1, B R Peters, E Hurliman
1Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA. ganesh785@gmail.com
What Is Known And Objective:
Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC).
Case Summary:
A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib.
What Is New And Conclusion:
There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.
Related Concept Videos
Cerebral Edema ll: Pathophysiology
Hepatic Encephalopathy